Lung Neoplasm
Conditions
Keywords
flexperc medical, microwave, ablation, phenoWave, phenoMapper
Brief summary
Evaluation of safety and technical feasibility of the phenoWave MW Ablation System for microwave ablation of lesions in the lung.
Detailed description
This study is a prospective, single-arm, single-center, study to evaluate the safety and technical feasibility of using the phenoWave MW Ablation System to deliver microwave energy for ablation of lesions in the lung.
Interventions
DEVICEFlexible Bronchoscopic Microwave Ablation
The phenoWave flexible microwave ablation system will be used to perform soft tissue ablation in the lungs under image guidance.
Sponsors
NIH/NCI - Grant award number: R01CA218357
phenoMapper, LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to 77 Years
Healthy volunteers
No
Inclusion criteria
* Age 45-77 years at screening. * Confirmed NSCLC or solitary metastatic (oligometastatic) or pulmonary metastases from an extra thoracic primary tumor lung nodule through diagnostic biopsy * Must be eligible for curative lung resection (lobectomy). * For primary tumor, pre-ablated parenchymal tumor/lesion size ≥ 20 mm if NSCLC, or ≥ 10 mm for metastatic disease in diameter as measured from pre-operative CT image. * Willing to participate in all aspects of study protocol for duration of study. * Able to understand study requirements. * Signs informed consent form. * Boundary of tumor is at least 15 mm away from the pleura wall and/or fissure.
Exclusion criteria
* Any contraindication to bronchoscopy, for example: * Untreatable life-threatening arrhythmias. * Inability to adequately oxygenate the patient during the procedure. * Acute respiratory failure with hypercapnia (unless the patient is intubated and ventilated). * Recent myocardial infarction. * Uncorrectable coagulopathy. * Known coagulopathy. * Platelet dysfunction or platelet count \< 100 x 109 cells/L OR taking anticoagulant or antiplatelet agents that cannot be safely ceased in the opinion of the pulmonologist or surgeon. * History of major bleeding with bronchoscopy. * Suspected pulmonary hypertension. * Moderate-to-severe pulmonary fibrosis. * Severe emphysema (GOLD III/IV) or chronic obstructive pulmonary disease (COPD) within 3cm of tumor/lesion boundary: prior COPD assessment data is evaluated and PI consent is required. * Bullae \>5 centimeter (cm) located in vicinity of target tumor/lesion. * Any other severe or life-threatening comorbidity that could increase the risk of bronchoscopic MWA, for example: * American Society of Anesthesiologists (ASA) physical status classification \>P3 * Stage 3 heart failure * Severe cachexia * Severe respiratory insufficiency or hypoxia * Ongoing systemic infection. * Contraindication to general anesthesia. * Inability to stop anticoagulants (e.g., heparin, Warfarin) or antiplatelet agents (e.g. aspirin, clopidogrel) prior to procedure. * Participation in any other study in last 30 days. * Breastfeeding women or females of childbearing potential with a positive pregnancy test prior to the procedure or the intent to become pregnant during the study. * Life expectancy of less than 6 months. * Prior radiation therapy treatment in the target lobe. * Implantable pacemaker or defibrillator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety - AE occurrence | up to 7 days post ablation | Incidence of complications and occurrence of Adverse Events (AEs) |
| Safety - AE frequency | up to 7 days post ablation | Frequency of AEs |
| Safety - ablated tissue assessment | up to 7 days post ablation | Percentage of ablated tissue within tumor boundary as assessed on gross and/or histologic evaluation |
| Technical Feasibility | up to 7 days post ablation | Evidence of thermal ablation in portion of the tumor as assessed on histopathology |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Navigational Success | Immediately after completion of procedure (day 0) | Measured distance of phenoWave device tip relative to the planned position from CT data |
| Procedural Measures | Immediately after completion of procedure and navigation to the target (day 0) | Total procedure time and navigation time to position the device |
Countries
Australia
Contacts
Primary ContactHenky Wibowo, MSc
Outcome results
None listed